DOCSLIB.ORG

HVM-Connect-Issue-9-May-2020.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

The Ventilator Challenge: CPI joins national COVID-19 Restarting operations? Two months of success vaccine taskforce Work safety culture doesn’t happen by accident Page 4 Page 12 Page 14 High Value Manufacturing news Issue 09 | May 2020 COVID19 sPECIAL iSSUE Free technical pack doWNLOADS iNTUBATION SHIELDS: Page 8 Face Shields: Page13 HVM CONneCT Welcome to CONTENTS FeatureS The Ventilator Challenge: 4 hvm connect Two months of success CPI joins national taskforce to 12 Your quarterly high value manufacturing update develop COVID-19 vaccine Restarting operations? 14 We live in unprecedented times. In generation- Work safety culture doesn’t defining moments such as this, we are all happen by accident judged by our actions. Whether by following social distancing measures, delivering key NEWS supplies or by supporting the frontline, we all have a role to play in helping flatten the viral NMIS appoints first CEO 3 curve and enabling our NHS to cope with the HVM Catapult CEO defers retirement 3 Rosa Wilkinson sudden influx of patients. AMRC rising to the ventilator 6 Communications The HVM Catapult and wider manufacturing Director challenge HVM Catapult community have played a vital role in the national response to the COVID-19 outbreak. In MTC develops intubation shield to 8 protect NHS staff this edition of HVM Connect, we look at how HVM Catapult Centres have been using their Navigating the deisgn to manufacture 9 insight, connections and facilities to support the journey national effort whether that’s in the development WMG helps British taskforce with new 9 of new products, creation of vital PPE or, of non-invasive ventilator course, in scaling up the manufacture of the life- NCC prints protective face shields for 10 saving ventilators our hospitals need. Bristol hospitals I’m pleased to say that the work we are doing is AMRC 3D prints protective face 11 not just about responding to today’s demands. shields for NHS workers We know that even when we emerge from the MTC provides free face shield design 13 crisis, our manufacturers will face significant to combat coronavirus challenges in a world that could look and feel Low-oxygen scuba rebreather 15 very different. The good news is that the HVM repurposed to help coronavirus Catapult’s teams are already gearing up to patients ensure that firms are match fit when they step Manufacturing the future workforce 16 out into the ‘new normal’ that will follow this period of lock down. SUPPORT We all know that a period of ‘downtime’ can COVID-19 funding opportunities 18 give the room to think about new ways of Work with us 18 doing things. It can also allow time to forge relationships with new partners. Through this crisis, the UK’s engineering firms have already shown the amazing results they can deliver. Keep up to date Helping them to connect even better with the Get all the latest news from the HVM Catapult: UK’s world-leading research base will help them @HVM_Catapult to shine even more brightly on the global stage. linkedin.com/company/ The HVM Catapult is committed to helping high-value-manufacturing-catapult/ them to do so. hvm.catapult.org.uk 2 High Value Manufacturing Catapult HVM CONnecT NMIS appoints first CEO he National Manufacturing T Institute Scotland, the overarching group for our centre the AFRC, has announced that John Reid HVM Catapult CEO has been appointed as Chief Executive Officer to lead the growth and development of defers retirement the world-leading industry- led manufacturing research D ick Elsy, Chief Executive I want to play my full part in and development facilities Officer of the High Value mobilising the outstanding at the heart of the Advanced Manufacturing Catapult, has resources of the High Value Manufacturing Innovation announced that he will defer his Manufacturing Catapult to District Scotland led by planned retirement to support underpin their success until the Renfrewshire Council. the manufacturing sector’s situation stabilises and I can response to the coronavirus hand over to a successor.” John will take up position outbreak. in August after successfully Responding to Mr Elsy’s leading the Michelin-Scotland Mr Elsy announced in announcement, Allan Cook, Innovation Parc (MSIP) in January that he would retire CBE, Chair of the High Value Dundee. Prior to leading from the HVM Catapult in Manufacturing Catapult said: MSIP John held the position August this year. Yesterday, “I am delighted that Dick has of General Manager at the in response to challenges UK generously decided to defer Michelin tyre plant on the manufacturers will face during his departure from the High same site. the coronavirus outbreak, Dick Value Manufacturing Catapult. confirmed that he would defer His decision is typical of Dick’s John’s appointment his retirement to support the commitment to HVMC and the further strengthens the national response to the virus. wider manufacturing sector. leadership team for the group, He said: “Coronavirus His deep understanding of UK which includes the new manufacturing and his tireless flagship facility being built presents immense challenges for the UK’s manufacturers. passion for supporting the next to Glasgow Airport that sector’s businesses through was recently granted planning In the short term they will be called on to step up to supply innovation are vital qualities at permission by Renfrewshire a time when companies are Council. the nation’s needs at an extraordinary moment in our facing exceptional demands history. Looking further ahead, and an uncertain future READ MORE they will need to be strong to economy.” weather the shock that the virus has given our economy. read more High Value Manufacturing Catapult 3 HVM CONneCT 4 High Value Manufacturing Catapult HVM CONnecT FEATURE The Ventilator Challenge: Two months of success entilatorChallengeUK, device. The ventilator received paraPAC plus™ ventilator with V the consortium of UK MHRA approval on 15 April three brand-new production aerospace, automotive and 2020, becoming the first newly sites established in the past medical businesses that has adapted ventilator design to be 8 weeks at GKN Aerospace’s come together to produce at- given regulatory authorisation facilities at Luton and at Cowes scale medical ventilators for the as part of the UK Government’s and Rolls Royce at Filton. NHS, celebrated two-months fight against COVID19. In total, the 33-strong since it was formed last week. As well as producing the consortium has seen over Led by our very own Dick Penlon Prima ESO2 device, 5,500 people working around Elsy, the Consortium has VentilatorChallengeUK has the clock across nine sites focused its efforts on scaling also supported Smiths Group to deliver both models of up production of two devices in scaling up the delivery of its ventilator into the NHS. since its formation on 19th Together, Penlon and March 2020. One an existing Smiths would ordinarily design made by Smiths Group, have combined capacity to the other a new device based produce between 50 and 60 on an adaptation of existing ventilators per week. Today technology from Oxfordshire- the consortium is producing based Penlon. between 100-200 of the VentilatorChallengeUK has combined units per day as worked closely with Penlon to it seeks to deliver increased modify and scale up production ventilator capacity to the UK. of its Penlon Prima ES02 High Value Manufacturing Catapult 5 HVM CONneCT We have covered an incredible amount of ground in the two months since the Consortium was formed. The progress we have made is testament to the effort and energy brought to the challenge by every member of the VentilatorChallengeUK Consortium team. They have never wavered in their determination to make sure AMRC rising to that our NHS always has the number of ventilators it needs to treat this virus. the ventilator Although the UK is widely accepted to have passed the peak of infections in this first challenge phase of the pandemic, we are continuing to uturistic headsets pandemic reaches its peak and scale up our production F programmed to enable risks overwhelming the ability capabilities to make sure skilled aerospace and of NHS doctors and nurses to that there is always a automotive production line treat a sudden surge in patients entilator available when a operatives to rapidly switch to suffering from the virus. The patient needs it should a the manufacture of 10,000 life- industrial consortium, Ventilator second wave strike the UK. saving medical ventilators were Challenge UK, came together I look forward to seeing rushed from the Advanced after the Prime Minister, Boris VentilatorChallengeUK Manufacturing Research Johnson, made a plea for an deliver even more ventilators Centre (AMRC), part of the High additional 50,000 ventilators to over the coming weeks.” Value Manufacturing (HVM) be delivered to the NHS within Catapult, to sites across the UK a matter of weeks. DIck Elsy last week. At the same time, Under the leadership of CEO, HVM Catapult AMRC Cymru was turned into the HVM Catapult, the AMRC a production facility for the and the Nuclear AMRC are at devices. the heart of a multi-faceted The augmented reality campaign to deliver the For more information and equipment is critical to the additional ventilators, the first press enquiries, please visit the success of a powerful industrial of which will be coming off VentilatorChallengeUK website. consortium which has come production lines around the together to accelerate the UK as early as next week, Find out more production of thousands of according to the Chancellor ventilators before the Covid-19 of the Duchy of Lancaster, 6 High Value Manufacturing Catapult HVM CONnecT Michael Gove. The consortium is focusing production on two existing ventilator designs which meet the high-level specification for a Rapidly Manufactured Ventilator System (RMVS) developed by clinicians and the Medicines and Healthcare products Regulatory Agency (MHRA).
Recommended publications
  • 23 April 2020 Update

    23 April 2020 Update

    20 April – 23 April 2020 Contents I. Summary .............................................................................................................................1 II. European Union .................................................................................................................5 III. France ...............................................................................................................................6 IV. Italy ...................................................................................................................................7 V. Germany ............................................................................................................................8 VI. Spain ...............................................................................................................................10 VII. United Kingdom .............................................................................................................10 I. SUMMARY Number of cases: 1,009,762 (including the UK) Number of deaths: 108,223 • The EU Executive Steering Group on Shortages of Medicines Caused by Major Events held a meeting on 15 April to discuss the progress of the measures regarding availability of medicines for European patients during the COVID-19 pandemic. They also updated the Q&A document on regulatory expectations for medicinal products for human use during the COVID-19 pandemic on 20 April. On 21 April, they set-up the fast-track system to support essential medicines for COVID-19 treatment,
  • Written Evidence from Spotlight on Corruption1 (PGG18) the Public

    Written Evidence from Spotlight on Corruption1 (PGG18) the Public

    Written evidence from Spotlight on Corruption1 (PGG18) The Public Administration and Constitutional Affairs Committee Propriety of governance in light of Greensill inquiry Introduction The revelations arising from the Greensill affair and its fallout, coming alongside other recent and ongoing scandals, have exposed significant weaknesses in the UK system for managing conflicts of interest, lobbying, and business appointments. This is a vital opportunity to bring the UK’s standards landscape up to date, and to ensure that integrity and ethics in government are regulated in a way that befits a modern democracy. Taking action to strengthen the UK’s integrity and ethics framework would benefit the UK by helping to: build trust in politicians and government; strengthen the stability, predictability and attractiveness of the UK as a place to do business; give the UK greater credibility on the international stage in promoting democracy and good governance; and implement outstanding recommendations made by international bodies such as the UN and Council of Europe about how the UK can improve its integrity and ethics framework to prevent and tackle corruption. Key Recommendations 1. Integrity and Ethics legislation. The government should consult on the introduction of an Integrity and Ethics Bill, by the spring of 2022, which gives legislative effect to: the Law Commission’s recommendations on the introduction of a corruption in public office offence; recommendations made by international bodies to put ACOBA and the Independent Advisor on Ministerial Interests on a statutory footing; recommendations that are likely to be made by the Committee on Standards in Public Life’s Standards Matters 2.0 review in the Autumn of 2021; and recommendations likely to be made from both the Boardman review and parliamentary committees such as PACAC, including legislative reform to the Lobbying Act.
  • UK COVID-19 Vaccines Delivery Plan

    UK COVID-19 Vaccines Delivery Plan

    UK COVID-19 vaccines delivery plan Published 11 January 2021 Contents 1. Ministerial foreword ....................................................................................................... 3 2. Executive summary and scope ..................................................................................... 4 Supply .............................................................................................................................. 5 Prioritisation ...................................................................................................................... 6 Places ............................................................................................................................... 7 People .............................................................................................................................. 8 Tracking our progress ....................................................................................................... 9 3. Supply ......................................................................................................................... 10 Developing new vaccines ............................................................................................... 10 Ensuring vaccines meet strict safety standards for deployment ..................................... 17 Building UK manufacturing capability ............................................................................. 21 4. Prioritisation ...............................................................................................................
  • COVID-19 Interim Vaccination Plan V.5 Pennsylvania

    COVID-19 Interim Vaccination Plan V.5 Pennsylvania

    COVID-19 Interim Vaccination Plan V.5 Pennsylvania PA COVID-19 Vaccine Task Force/PA Department of Health JANUARY 19, 2021 |VERSION 5.0 PENNSYLVANIA COVID-19 INTERIM VACCINATION PLAN Table of Contents Introduction……………………………………………………………………………………………………………………………………….2 Section 1: COVID-19 Vaccination Preparedness Planning ......................................................................... 3 Section 2: COVID-19 Organizational Structure and Partner Involvement ................................................. 4 Section 3: Phased Approach to COVID-19 Vaccination ........................................................................... 11 Section 4: Critical Populations ................................................................................................................. 17 Section 5: COVID-19 Provider Recruitment and Enrollment ................................................................... 21 Section 6: COVID-19 Vaccine Administration Capacity ........................................................................... 25 1. Health and Medical Infrastructure .......................................................................................... 25 2. Occupational Health Clinics and Closed Points of Dispensing (PODs) ..................................... 26 3. Expanded Outreach to Ensure Vaccine Access ........................................................................ 27 4. Staffing ....................................................................................................................................
  • Role and Responsibilities of the Chair of the Vaccine Taskforce

    Role and Responsibilities of the Chair of the Vaccine Taskforce

    Chair of the Vaccine Taskforce Information pack for applicants Closing date: Midday on Friday 14 May 2021 Reference no: VAC-1775 Follow us on Twitter @appointmentsdh Table of Contents Section 1: Role, responsibilities and person specification.................................................... 2 Section 2: How to apply ....................................................................................................... 4 2.1 Making an application ............................................................................................. 4 2.2 The selection process ............................................................................................. 7 2.3 Eligibility criteria ...................................................................................................... 9 2.4 How we will manage your personal information .................................................... 10 Chair of the Vaccine Taskforce - Information pack for applicants Section 1: Role and responsibilities of the Chair of the Vaccine Taskforce The Chair must enable the Vaccine Taskforce to achieve their three core objectives during the pandemic period: a. To secure access to promising vaccine/s for the UK population. b. To make provision for international distribution of vaccines. c. To strengthen the UK’s onshore capacity and capability in vaccine development, manufacturing, and supply chain to provide resilience for this and future pandemics. In recognising that the Taskforce has now been in existence for over a year, delivering these objectives
  • WHO Backs Rollout of Astrazeneca Vaccine

    WHO Backs Rollout of Astrazeneca Vaccine

    this week TWINS page 423 • VACCINATING CHILDREN page 424 • BRITISH CYCLING page 427 FRANK HOERMANN/DPA/PA/ALAMY FRANK WHO backs rollout of AstraZeneca vaccine Doctors have warned of the risks associated On 16 March WHO’s chief scientist, Soumya The World Health Organization with pausing or delaying vaccination Swaminathan, said, “We do not want has urged people not to panic programmes against covid-19, as the people to panic, and we would, for the time amid reports of blood clotting number of European countries that have being, recommend that countries continue disorders in patients receiving the vaccine halted use of the Oxford University and vaccinating with AstraZeneca . So far, we AstraZeneca vaccine rose to 16. do not fi nd an association between these Denmark, Norway, Bulgaria, Iceland, events and the vaccine.” France, Germany, Italy, Spain, Portugal, The EMA said there had been 30 reports Slovenia, and Cyprus have suspended all of thromboembolic events among nearly use of the vaccine. Five other countries fi ve million people given the AstraZeneca (Austria, Estonia, Latvia, Lithuania, and vaccine in the European Economic Area. Luxembourg) have paused the use of a AstraZeneca has said 37 blood clots have LATEST ONLINE batch of a million doses of the vaccine. been reported among more than 17 million NHS and social The moves came after reports of people vaccinated in the EU and Britain. care need an extra blood clotting disorders. The Norwegian Five of the cases were deep vein thrombosis, £12bn to get back Medicines Agency said last week it was and 22 were pulmonary embolisms.
  • UKC Monthly Summary 2020 July.Odt

    UKC Monthly Summary 2020 July.Odt

    UK COLUMN CONTENT – July 2020 https://www.ukcolumn.org/ukcolumn-news-archive 01st July 2020 Brian Gerrish and Mike Robinson with today's UK Column News. START – Good news: excess mortality rate falls below five-year average Leicester local lockdown – police to spot-check cars leaving the restricted zone… Government provides details without showing any evidence to support them SAGE recommended ramping up fear and turning communities against each other The Ferguson effect: a similar situation occurred with Foot & Mouth – community division This policy seems deliberate by the UK ‘government of occupation’ Increased Covid-19 testing will obviously result in an increase in reported cases Is this a trial run and normalisation of ‘City State’ powers…? CoronaVirus found in waste water as early as March 2019 in Spain The spike in excess deaths across the world happened after lockdown… 15:49 – More fear: schools, hospitals and offices told to prepare for ‘marauding’ terror attacks Mail Online: is your teen secretly struggling with depression…? Mail Online: workers’ health starts to fail at the age of 59 MSM complains about Covid-19 infodemic – the ‘wrong’ kind of information… 19:28 – David Noakes (GcMAF) contact information CoronaVirus: Upper Crust owner blames lockdown for 5,000 UK redundancies Michael Gove quotes Franklin Delano Roosevelt in Brexit comments Gove suggests that change is coming to the UK Civil Service Boris announces a ‘new deal’ - ‘the opportunity is massive’ The MainStream Media reaction to Boris…? Nothing, silence… MSM too busy
  • MCC VA COVID-19 Vaccine Provider FAQ May 2021

    MCC VA COVID-19 Vaccine Provider FAQ May 2021

    COVID-19 Vaccine Provider FAQs We are actively monitoring COVID-19 vaccine developments. Below you will find helpful information and answers to some of the most frequently asked questions about COVID-19 vaccines. Magellan Complete Care has a COVID-19 Vaccine Taskforce comprised of experts, including clinicians, health plan leadership, and pharmacy network team members that meets regularly to discuss the latest developments and plan support. We are monitoring government guidance at the federal and state levels. We are taking steps to ensure you have the information you need as the information and guidelines are made available by federal and state agencies. Vaccine Development and Distribution Operation Warp Speed (OWS) was set up by the White House to coordinate efforts among federal government entities, states, and private sector partners. It aims to accelerate the testing, supply, development, and distribution of safe and effective vaccines, therapeutics, and diagnostics. There are many government agencies involved in helping with the COVID-19 pandemic. A few of the key agencies are listed below for your reference: • Food and Drug Administration (FDA) – The FDA reviews and approves or authorizes safe and effective vaccines. • Centers for Disease Control and Prevention (CDC) – The CDC is responsible for controlling the introduction and spread of infectious diseases. • Advisory Committee on Immunization Practices (ACIP) – ACIP is a committee within the CDC that provides advice and guidance on effective control of vaccine-preventable diseases in the U.S. civilian population. • National Academies of Science Engineering & Medicine (NASEM) – The National Institutes of Health (NIH) and CDC have tasked NASEM to develop a plan for equitable allocation of vaccines.
  • COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea

    COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea

    International Journal of Environmental Research and Public Health Article COVID-19 Vaccine Priority Strategy Using a Heterogenous Transmission Model Based on Maximum Likelihood Estimation in the Republic of Korea Youngsuk Ko 1 , Jacob Lee 2, Yeonju Kim 3, Donghyok Kwon 3 and Eunok Jung 1,* 1 Department of Mathematics, Konkuk University, Seoul 05029, Korea; [email protected] 2 Division of Infectious Disease, Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24252, Korea; [email protected] 3 Division of Public Health Emergency Response Research, Korea Disease Control and Prevention Agency, Cheongju 28159, Korea; [email protected] (Y.K.); [email protected] (D.K.) * Correspondence: [email protected] Abstract: (1) Background: The vaccine supply is likely to be limited in 2021 due to constraints in manufacturing. To maximize the benefit from the rollout phase, an optimal strategy of vaccine allocation is necessary based on each country’s epidemic status. (2) Methods: We first developed a heterogeneous population model considering the transmission matrix using maximum likelihood estimation based on the epidemiological records of individual COVID-19 cases in the Republic of Korea. Using this model, the vaccine priorities for minimizing mortality or incidence were investigated. (3) Results: The simulation results showed that the optimal vaccine allocation strategy to minimize the mortality (or incidence) was to prioritize elderly and healthcare workers (or adults) as Citation: Ko, Y.; Lee, J.; Kim, Y.; long as the reproductive number was below 1.2 (or over 0.9). (4) Conclusion: Our simulation results Kwon, D.; Jung, E. COVID-19 Vaccine support the current Korean government vaccination priority strategy, which prioritizes healthcare Priority Strategy Using a workers and senior groups to minimize mortality, under the condition that the reproductive number Heterogenous Transmission Model remains below 1.2.
  • Whole Day Download the Hansard

    Whole Day Download the Hansard

    Tuesday Volume 678 30 June 2020 No. 78 HOUSE OF COMMONS OFFICIAL REPORT PARLIAMENTARY DEBATES (HANSARD) Tuesday 30 June 2020 © Parliamentary Copyright House of Commons 2020 This publication may be reproduced under the terms of the Open Parliament licence, which is published at www.parliament.uk/site-information/copyright/. 133 30 JUNE 2020 134 Wendy Morton: That is a really important point. The House of Commons Prime Minister has made it clear that equitable access is an integral part of the UK’s approach to vaccine Tuesday 30 June 2020 development and distribution. Only last weekend, he emphasised how all the world’s leaders have a moral duty to ensure that covid-19 vaccines are truly available The House met at half-past Eleven o’clock to all. That is why the UK has contributed more than £313 million of UK aid to CEPI, the COVID-19 PRAYERS Therapeutics Accelerator, the Access to COVID-19 Tools (ACT) Accelerator, and the Foundation for Innovative New Diagnostics. We have also committed £1.65 billion [MR SPEAKER in the Chair] to Gavi over five years to strengthen immunisation for Virtual participation in proceedings commenced (Order, vaccine preventable disease in vulnerable countries. 4 June). Andrew Jones: Around the world, there are more than [NB: [V] denotes a Member participating virtually.] 100 programmes to develop a coronavirus vaccine. Can my hon. Friend confirm that our global diplomatic presence is assisting UK companies and universities to Oral Answers to Questions participate in those programmes, basically by using their local networks to highlight the significant expertise that the UK can contribute, but also vice versa to identify where those contacts can contribute to UK-based FOREIGN AND COMMONWEALTH OFFICE programmes, because this is truly a global effort? The Secretary of State was asked— Wendy Morton: Yes, our overseas network is working actively around the globe, particularly through our Covid-19 Vaccine world-leading science and innovation network.
  • COVID-19 Vaccine Faqs from Piedmont Healthcare

    COVID-19 Vaccine Faqs from Piedmont Healthcare

    January 7, 2021 Piedmont’s Vaccine Taskforce FAQs In response to a request from the State, Piedmont has created a cross functional, system-level taskforce to create a plan for how we will assist in deploying a COVID-19 vaccine. Our deployment is in accordance State and Federal agency guidelines. Below are FAQs the Taskforce has developed for all of our stakeholders – patients and workforce members. Use the links below to navigate to various sections of this document. General COVID-19 Vaccine Questions ................................................................................................................................................... 2 Vaccine Development and Availability ............................................................................................................................................ 2 Vaccine Benefits ............................................................................................................................................................................ 2 Vaccine Safety and Efficacy ........................................................................................................................................................... 3 Manufacturer specific vaccine information ...................................................................................................................................... 3 Vaccine Considerations in Special Populations .............................................................................................................................
  • Legal-Graphics' 6-26-21 COVID Timeline

    Legal-Graphics' 6-26-21 COVID Timeline

    Number of days since first sign of virus Overview: Year 2 of COVID Year 2 Nov. 23, 2020 Dec. 3, 2020 Dec. 11, 2020 Dec. 21, 2020 Dec. 30, 2020 Jan. 7, 2021 Jan.Jan. 14,7, 2021 2021 of COVID-19 Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Worldwide Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths Coronavirus Deaths over 1,400,000 over 1,500,000 over 1,600,000 over 1,700,000 over 1,800,000 over 1,900,000 over 1,900,0002,000,000 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 Link to Nov. 16, 2020 Nov. 18, 2020 Nov. 21, 2020 Nov. 25, 2020 Nov. 27, 2020 Nov. 30, 2020 Dec. 3, 2020 Dec. 6, 2020 Dec. 8, 2020 Dec. 11, 2020 Dec. 14, 2020 Dec. 17, 2020 Dec. 21, 2020 Dec. 22, 2020 Dec. 26, 2020 Dec. 29, 2020 Dec. 31, 2020 Jan. 3, 2021 Jan. 5, 2021 Jan. 8, 2021 Jan. 11, 2021 Jan. 13, 2021 Jan. 17, 2021 Source Moderna says data FDA allows US cases top Picture of US Demand for live Moderna to request Map showing US UK gears up for Chart of cumulative Pfizer vaccine to be How do the Pfizer Vaccinations reach How the Pfizer Vaccines across Could AZD7442 Map showing How vaccinations Interactive US Map It’s lockdown No.